Post-marketing safety of lecanemab: a real-world study based on FAERS database, multicenter cohort and network pharmacology - Takeaways - MDSpire

Post-marketing safety of lecanemab: a real-world study based on FAERS database, multicenter cohort and network pharmacology

  • By

  • Xiaoxuan Xing

  • Ke Wang

  • Yingnan Feng

  • Chao Wu

  • Lihua Jia

  • Huiying Li

  • Zhiyong Wen

  • Yinan Tang

  • Zhizhou Wang

  • Xiaotong Zhang

  • Xiaoxi Li

  • Yiming Hua

  • Lan Zhang

  • Xianzhe Dong

  • June 22, 2026

  • 0 min

Share

  • 1

    Lecanemab is a monoclonal antibody approved for Alzheimer's disease, specifically for patients with mild cognitive impairment or mild dementia.

  • 2

    The study analyzed adverse events related to lecanemab using the FAERS database and a multicenter cohort from five tertiary hospitals.

  • 3

    In the FAERS analysis, 12 of 41 positive signals were identified, with 75% related to nervous system disorders, primarily ARIA.

  • 4

    In the cohort study, 29.05% of patients experienced adverse events, with infusion-related reactions being the most common.

  • 5

    Age was identified as a risk factor for adverse events, while pre-treatment significantly reduced the incidence of these events.

Original Source(s)

Post-marketing safety of lecanemab: a real-world study based on FAERS database, multicenter cohort and network pharmacology

  • by Xiaoxuan Xing, Ke Wang, Yingnan Feng, Chao Wu, Lihua Jia, Huiying Li, Zhiyong Wen, Yinan Tang, Zhizhou Wang, Xiaotong Zhang, Xiaoxi Li, Yiming Hua, Lan Zhang, Xianzhe Dong

  • June 22, 2026

Related Content

Effectiveness of eHealth Interventions in Alleviating Burden on Informal Caregivers of People With Dementia: Systematic Review and Meta-Analysis of Randomized Controlled Trials

Pain differences in cognitive impairment appear only during active motor tasks

Digital life stories: Navigating together – an observation study of healthcare professionals and people living with dementia